Neovacs

About Neovacs

Neovacs, founded in 1993 as a spin-off from Pierre and Marie Curie University, specializes in developing innovative immunotherapy solutions targeting autoimmune diseases and allergies. The company leverages its patented Kinoid technology to create therapeutic vaccines that modulate the immune system. Neovacs operates primarily in the biotechnology and medical technology sectors, serving clients that include healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research and development (R&D) and strategic investments in biotech and medtech startups. Revenue is generated through product development, licensing agreements, and partnerships with other companies in the healthcare industry. Neovacs was introduced on the Euronext Growth market in Paris in 2010, providing it with access to capital for further growth and innovation. The company is supported by a dedicated international scientific committee and experienced leadership team, ensuring a strong focus on advancing its scientific expertise and commercial success.